Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Can NICE deliver on its funding promises?

Can NICE deliver on its funding promises? What started with a positive recommendation last January for Astellas’ Xtandi in prostate cancer has certainly provided much work for the industry too.

Pfizer mulling product sale to streamline ops; sources

Pfizer mulling product sale to streamline ops; sources The Medivation deal brought in prostate cancer treatment Xtandi (enzalutamide), while buying Anacor gave the drugmaker a late-stage eczema candidate - crisaborole - tipped as a future blockbuster.

FDA starts speedy review of Merck/Pfizer's PD-L1 inhibitor

FDA starts speedy review of Merck/Pfizer's PD-L1 inhibitor The company has been buying in assets to flesh out its oncology portfolio, and in addition to avelumab also acquired Medivation for $14bn to add prostate cancer treatment Xtandi (enzalutamide) and

Astellas buys Ganymed to boost immuno-oncology pipeline

Astellas buys Ganymed to boost immuno-oncology pipeline Astellas has been working hard to build up its oncology portfolio, currently headed by prostate cancer treatment Xtandi (enzalutamide), which is partnered with Pfizer. ... The acquisition of Ganymed will enable Astellas to further expand our oncology

Pfizer decides against long-discussed break-up

Pfizer decides against long-discussed break-up Medivation adds another fast-growing prostate cancer treatment Xtandi (enzalutamide), which posted $1.9bn in sales last year.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics